ID   MOLT-3
AC   CVCL_0624
SY   Molt-3; MOLT 3; Molt 3; MOLT3; Molt3
DR   BTO; BTO:0001081
DR   CLO; CLO_0007824
DR   CLO; CLO_0051008
DR   EFO; EFO_0005265
DR   CLDB; cl3519
DR   CLDB; cl3521
DR   CLDB; cl3522
DR   CLDB; cl3523
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-1552
DR   BCRC; 60106
DR   BioSample; SAMN03470846
DR   BioSample; SAMN03471394
DR   BioSample; SAMN03472164
DR   BioSample; SAMN03473404
DR   BioSample; SAMN10989586
DR   Cell_Model_Passport; SIDM00153
DR   ChEMBL-Cells; CHEMBL3307556
DR   ChEMBL-Targets; CHEMBL614176
DR   CLS; 300116
DR   Cosmic; 724815
DR   Cosmic; 850193
DR   Cosmic; 913410
DR   Cosmic; 999756
DR   Cosmic; 1191701
DR   Cosmic; 1281377
DR   Cosmic; 1524845
DR   Cosmic; 2301561
DR   Cosmic; 2361367
DR   Cosmic; 2602923
DR   DepMap; ACH-000964
DR   DSMZ; ACC-84
DR   DSMZCellDive; ACC-84
DR   ECACC; 90021901
DR   GEO; GSM236793
DR   GEO; GSM236829
DR   HIVReagentProgram; ARP-12187
DR   IGRhCellID; MOLT3
DR   IZSLER; BS TCL 44
DR   JCRB; JCRB9048
DR   LiGeA; CCLE_717
DR   PharmacoDB; MOLT3_957_2019
DR   Progenetix; CVCL_0624
DR   RCB; RCB1164
DR   Wikidata; Q54906351
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=327080;
RX   PubMed=1086134;
RX   PubMed=2846092;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3856477;
RX   PubMed=3874327;
RX   PubMed=4547172;
RX   PubMed=4567231;
RX   PubMed=6220172;
RX   PubMed=6600440;
RX   PubMed=7630190;
RX   PubMed=8547074;
RX   PubMed=8608962;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=9933131;
RX   PubMed=10739008;
RX   PubMed=11986953;
RX   PubMed=12623853;
RX   PubMed=15472075;
RX   PubMed=17170727;
RX   PubMed=20215515;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://www.nibsc.org/Default.aspx?pageid=597&id=0010&theme=default
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 24-48 hours (CLS); ~40 hours (DSMZ).
CC   Karyotypic information: Hypertetraploid karyotype (ATCC).
CC   Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (PubMed=15472075; DepMap).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (PubMed=15472075; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Genome ancestry: African=0.91%; Native American=0%; East Asian, North=2.31%; East Asian, South=0%; South Asian=0.44%; European, North=66.02%; European, South=30.32% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood. Cell type=T-cell.
ST   Source(s): ATCC; CLS; COG; DSMZ; PubMed=25877200; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12 (ATCC; COG; DSMZ)
ST   CSF1PO: 11,12,13 (CLS; PubMed=25877200; RCB)
ST   D13S317: 11,12,13 (RCB)
ST   D13S317: 12,13 (ATCC; CLS; COG; DSMZ; PubMed=25877200)
ST   D16S539: 10,11,13 (RCB)
ST   D16S539: 11,12,14 (COG)
ST   D16S539: 11,13,14 (ATCC; PubMed=25877200)
ST   D16S539: 11,14 (DSMZ)
ST   D16S539: 11,14,15 (CLS)
ST   D18S51: 12,13,16,17 (CLS; DSMZ)
ST   D18S51: 13,17 (COG)
ST   D18S51: 13,17,18 (PubMed=25877200)
ST   D19S433: 14,15 (COG)
ST   D19S433: 14,15,16 (CLS; DSMZ)
ST   D1S1656: 15.3,16,16.3
ST   D21S11: 28,29,30,31 (DSMZ)
ST   D21S11: 29,30 (PubMed=25877200)
ST   D21S11: 29,30,31,32 (CLS)
ST   D2S1338: 22,23,24 (DSMZ)
ST   D2S1338: 23,24 (CLS; COG)
ST   D3S1358: 14,15,16,17 (COG)
ST   D3S1358: 15,16,17 (CLS; DSMZ; PubMed=25877200)
ST   D5S818: 12 (ATCC; PubMed=25877200)
ST   D5S818: 12,13 (CLS; DSMZ; RCB)
ST   D7S820: 7,8,9 (RCB)
ST   D7S820: 7,8,9,10 (CLS; DSMZ)
ST   D7S820: 8,10 (ATCC; COG; PubMed=25877200)
ST   D8S1179: 9,13,14,15 (CLS; PubMed=25877200)
ST   D8S1179: 9,14 (DSMZ)
ST   D8S1179: 9,14,15 (COG)
ST   FGA: 19,21,25 (CLS)
ST   FGA: 21,22,23,24 (PubMed=25877200)
ST   FGA: 22,23,24 (DSMZ)
ST   FGA: 22,24 (COG)
ST   Penta D: 8,13
ST   Penta E: 14,16
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 17 (ATCC; COG; PubMed=25877200)
ST   vWA: 17,18 (CLS; DSMZ; RCB)
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_0013 ! MOLT-4
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 29
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=1086134;
RA   Kaplan J., Peterson W.D. Jr.;
RT   "Detection of T-cell lymphoma-associated antigens on cord blood
RT   lymphocytes and phytohemagglutinin-stimulated blasts.";
RL   Cancer Res. 36:3471-3475(1976).
//
RX   PubMed=2846092; DOI=10.1182/blood.V72.5.1755.1755;
RA   Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W.,
RA   Streifel B.J., Kersey J.H.;
RT   "Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human
RT   T-lymphoid cell lines with rearrangement of chromosome 7.";
RL   Blood 72:1755-1760(1988).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3856477;
RA   Ohnuma T., Lo R.J., Scanlon K.J., Kamen B.A., Ohnoshi T., Wolman S.R.,
RA   Holland J.F.;
RT   "Evolution of methotrexate resistance of human acute lymphoblastic
RT   leukemia cells in vitro.";
RL   Cancer Res. 45:1815-1822(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=4547172; DOI=10.1093/jnci/53.3.655;
RA   Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.;
RT   "Cytogenetic study of human lymphoid T-cell lines derived from
RT   lymphocytic leukemia.";
RL   J. Natl. Cancer Inst. 53:655-660(1974).
//
RX   PubMed=4567231; DOI=10.1093/jnci/49.3.891;
RA   Minowada J., Onuma T., Moore G.E.;
RT   "Rosette-forming human lymphoid cell lines. I. Establishment and
RT   evidence for origin of thymus-derived lymphocytes.";
RL   J. Natl. Cancer Inst. 49:891-895(1972).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
//
RX   PubMed=7630190;
RA   Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D.,
RA   Findley H.W.;
RT   "Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines
RT   established from children with acute lymphoblastic leukemia.";
RL   Leukemia 9:1159-1161(1995).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8608962; DOI=10.1002/(SICI)1097-0215(19960328)66:1<29::AID-IJC6>3.0.CO;2-0;
RA   Takemura Y., Kobayashi H., Gibson W., Kimbell R., Miyachi H.,
RA   Jackman A.L.;
RT   "The influence of drug-exposure conditions on the development of
RT   resistance to methotrexate or ZD1694 in cultured human leukaemia
RT   cells.";
RL   Int. J. Cancer 66:29-36(1996).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11986953; DOI=10.1038/sj.leu.2402485;
RA   O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.;
RT   "N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to
RT   acute lymphoblastic leukemia cell lines, but not to non-malignant
RT   lymphocytes.";
RL   Leukemia 16:902-910(2002).
//
RX   PubMed=12623853; DOI=10.1182/blood-2002-07-2268;
RA   Schroeder U., Bernt K.M., Lange B., Wenkel J., Jikai J., Shabat D.,
RA   Amir R., Huebener N., Niethammer A.G., Hagemeier C., Wiebusch L.,
RA   Gaedicke G., Wrasidlo W., Reisfeld R.A., Lode H.N.;
RT   "Hydrolytically activated etoposide prodrugs inhibit MDR-1 function
RT   and eradicate established MDR-1 multidrug-resistant T-cell leukemia.";
RL   Blood 102:246-253(2003).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//